1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Wu S, Du R, Gao C, Kang J, Wen J and Sun
T: The role of XBP1s in the metastasis and prognosis of
hepatocellular carcinoma. Biochem Biophys Res Commun. 500:530–537.
2018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Terada T and Maruo H: Unusual extrahepatic
metastatic sites from hepatocellular carcinoma. Int J Clin Exp
Pathol. 6:816–820. 2013.PubMed/NCBI
|
4
|
Wolmarans E, Nel S, Durandt C, Mellet J
and Pepper MS: Side population: Its use in the study of cellular
heterogeneity and as a potential enrichment tool for rare cell
populations. Stem Cells Int. 2018:24721372018. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H, et al: The ABC transporter Bcrp1/ABCG2 is expressed in
a wide variety of stem cells and is a molecular determinant of the
side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Toyoda Y, Takada T and Suzuki H:
Inhibitors of human ABCG2: From technical background to recent
updates with clinical implications. Front Pharmacol. 10:2082019.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Choi YH and Yu AM: ABC transporters in
multidrug resistance and pharmacokinetics, and strategies for drug
development. Curr Pharm Des. 20:793–807. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Najafi M, Farhood B and Mortezaee K:
Cancer stem cells (CSCs) in cancer progression and therapy. J Cell
Physiol. 234:8381–8395. 2019. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chen L, Li YP, Li XX, Lu ZH, Zheng QH and
Liu QY: Isolation of 4,4′-bond secalonic acid D from the
marine-derived fungus Penicillium oxalicum with inhibitory property
against hepatocellular carcinoma. J Antibiot (Tokyo). 72:34–44.
2019. View Article : Google Scholar : PubMed/NCBI
|
10
|
Steyn PS: The separation and detection of
several mycotoxins by thin-layer chromatography. J Chromatogr A.
45:473–475. 1969. View Article : Google Scholar
|
11
|
Guru SK, Pathania AS, Kumar S, Ramesh D,
Kumar M, Rana S, Kumar A, Malik F, Sharma PR, Chandan BK, et al:
Secalonic acid-D represses HIF1α/VEGF-mediated angiogenesis by
regulating the Akt/mTOR/p70S6K signaling cascade. Cancer Res.
75:2886–2896. 2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang JY, Tao LY, Liang YJ, Yan YY, Dai
CL, Xia XK, She ZG, Lin YC and Fu LW: Secalonic acid D induced
leukemia cell apoptosis and cell cycle arrest of G(1) with
involvement of GSK-3beta/beta-catenin/c-Myc pathway. Cell Cycle.
8:2444–2450. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang H, Huang L, Tao L, Zhang J, Wang F,
Zhang X and Fu L: Secalonic acid D induces cell apoptosis in both
sensitive and ABCG2-overexpressing multidrug resistant cancer cells
through upregulating c-Jun expression. Acta Pharm Sin B. 9:516–525.
2019. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hu YP, Tao LY, Wang F, Zhang JY, Liang YJ
and Fu LW: Secalonic acid D reduced the percentage of side
populations by down-regulating the expression of ABCG2. Biochem
Pharmacol. 85:1619–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
National Research Council, . Guide for the
Care and Use of Laboratory Animals: 8th edition. The National
Academies Press. (Washington, DC). 2011.
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kunnumakkara AB, Diagaradjane P, Anand P,
Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S and
Aggarwal BB: Curcumin sensitizes human colorectal cancer to
capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and
CXCR4 expression in an orthotopic mouse model. Int J Cancer.
125:2187–2197. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wellner UF, Hopt UT and Brabletz T: Tumour
stem cells and metastasis. Zentralbl Chir. 135:318–322. 2010.(In
German). View Article : Google Scholar : PubMed/NCBI
|
19
|
Gravitz L: Liver cancer. Nature.
516:S12014. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Parisod L, Duran R, Denys A and Digklia A:
Treatment of advanced hepatocellular carcinoma: Novel agents and
role of local therapy. Rev Med Suisse. 13:1032–1034. 2017.(In
French). PubMed/NCBI
|
21
|
Challen GA and Little MH: A side order of
stem cells: The SP phenotype. Stem Cells. 24:3–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
McClements L, Annett S, Yakkundi A,
O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong
F, Short A, et al: FKBPL and its peptide derivatives inhibit
endocrine therapy resistant cancer stem cells and breast cancer
metastasis by downregulating DLL4 and Notch4. BMC Cancer.
19:3512019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang S, Zhang E, Long J, Hu Z, Peng J,
Liu L, Tang F, Li L, Ouyang Y and Zeng Z: Immune infiltration in
renal cell carcinoma. Cancer Sci. 110:1564–1572. 2019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Nandy SB and Lakshmanaswamy R: Cancer stem
cells and metastasis. Prog Mol Biol Transl Sci. 151:137–176. 2017.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Ward MP and Spiers JP: Protein phosphatase
2A regulation of markers of extracellular matrix remodelling in
hepatocellular carcinoma cells: Functional consequences for tumour
invasion. Br J Pharmacol. 174:1116–1130. 2017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
28
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: Multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
29
|
Giusca SE, Caruntu ID, Amalinei C and
Avadanei ER: Prognostic significance of MMP-9 and TIMP-1 in liver
metastases. Romanian journal of morphology and embryology =. Rev
Roum Morphol Embryol. 56:357–364. 2015.
|
30
|
Ogata Y, Ookita A and Kakegawa T:
Significance of MMP-9 and TIMP-1 production during liver metastasis
in colorectal cancer. Nihon Rinsho. 53:1811–1815. 1995.(In
Japanese). PubMed/NCBI
|
31
|
Wang D, Plukker JTM and Coppes RP: Cancer
stem cells with increased metastatic potential as a therapeutic
target for esophageal cancer. Semin Cancer Biol. 44:60–66. 2017.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Agliano A, Calvo A and Box C: The
challenge of targeting cancer stem cells to halt metastasis. Semin
Cancer Biol. 44:25–42. 2017. View Article : Google Scholar : PubMed/NCBI
|